Biogen Inc. has announced the approval of SKYCLARYS™ (omaveloxolone) by Health Canada as the first and only treatment in Canada specifically targeting the underlying mechanisms of Friedreich ataxia $(FA)$ in patients aged 16 and older. This approval was granted under Health Canada's Priority Review process. Despite this significant milestone, Biogen has expressed disappointment over the recommendation by INESSS against listing SKYCLARYS for reimbursement in Quebec, which would leave FA patients in the province without public access to this critical treatment. The approval of SKYCLARYS marks a breakthrough for FA patients, addressing a major gap in care and offering hope for improved quality of life. The decision now awaits further consideration for reimbursement by Quebec authorities.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。